Viljoen A, Hoxer CS, Johansen P, Diabetes, Obesity and Metabolism 2019; 21(3): 611-621.
, , Bain SC. Evaluation of the long‐term cost‐effectiveness of once‐weekly semaglutide versus dulaglutide for the treatment of type 2 diabetes mellitus in the UK.Diabetes Therapy 2019; 10(1): 159-176.
, Russel-Szymczyk M, Liidemann G, Volke V, . Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia.Petitjean A, BMC Cancer 2019; 19(1): 140.
, , Tehard B, Roze S. Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France.Roze S, Clinicoeconomics and Outcomes Research 2019; 11: 73-82.
, de Portu S, Delbaere A, de Brouwer B, de Valk HW. Cost-effectiveness of sensor-augmented insulin pump therapy vs continuous subcutaneous insulin infusion in patients with type 1 diabetes in the Netherlands.Jendle J, Diabetes Technology and Therapeutics 2019; 21(3): 110-118.
, de Portu S, , Roze S. Cost-effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes.Billings LK, Mocarski M, Basse A, Clinicoeconomics and Outcomes Research 2019; 11: 271-282.
, , Jodar E. Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA.BMC Urol 2019; 19(1): 19.
, Takizawa C, . Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada.Johansen P, Advances in Therapy 2019; 36(5): 1190-1199.
, Iyer NN, Dang-Tan T, . A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.Roze S, Diabetes Therapy 2019; 10(2): 563-574.
, Delbaere A, Bjornstrom K, de Portu S, , Honkasalo M. Cost-Effectiveness of Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Patients with Poorly Controlled Type 2 Diabetes in Finland.Diabetes Therapy 2019; 10(2): 493-508.
, Russel-Szymczyk M, Holík P, Rychna K, . Treating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixi.Mezquita Raya P, Ampudia Blasco FJ, Diabetes, Obesity and Metabolism 2019; 21: 1349–1356.
, Martin V, Thorsted BL, Basse A, Price H. Evaluating the long-term cost-effectiveness of IDegLira for type 2 diabetes in Spain based on real-world clinical evidence.Gæde P, Johansen P, Tikkanen CK,Diabetes Therapy 2019; 10(4): 1297-1317.
, , . Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.Advances in Therapy 2019; 36(8): 2034-2051.
, Russel-Szymczyk M, Psota M, Hlavinkova L, . The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.Journal of Diabetes Science and Technology 2019; 13(5): 910-918.
, Mitchell BD, Bajpai S, Osumili B, . Nasal Glucagon Versus Injectable Glucagon for Severe Hypoglycemia: A Cost-Offset and Budget Impact Analysis.Applied Health Economics and Health Policy 2019; 17(5): 615-627.
, , Marso SP, Andersen A, Gundgaard J, Hallén N, Tutkunkardas D, Magnuson EA, Buse JB; DEVOTE study group. Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16).BMJ Open Diabetes Research and Care 2019; 7: e000705.
, , Moes RGJ, Huisman EL, Vandebrouck T, Wolffenbuttel B. Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands.Clinicoeconomics and Outcomes Research 2019; 11: 605-614.
, Montagnoli R, Lastoria G, Parekh W, Markert M, . Value For Money In The Treatment Of Patients With Type 2 Diabetes Mellitus: Assessing The Long-Term Cost-Effectiveness Of IDegLira Versus iGlarLixi In Italy.Advances in Therapy 2019; 36(12): 3483-3493.
, Hansen BB, Ericsson Å, Kallenbach K, Ali SN, Dang-Tan T, , . Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States.Roze S, Diabetes Technology and Therapeutics 2019; 21(12): 727-735.
, de Portu S, Özdemir Saltik AZ, Akgül T, Deyneli O. Cost-Effectiveness of Sensor-Augmented Insulin Pump Therapy Versus Continuous Insulin Infusion in Patients with Type 1 Diabetes in Turkey.